XI'AN INTERNATIONAL MEDICAL INVESTMENT COMPANY LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.84 CNY | +0.34% |
|
-0.34% | -27.99% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 53.09 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -27.99% | 1.82B | - | ||
| -18.96% | 16.46B | B+ | ||
| +3.60% | 12.53B | B | ||
| +3.98% | 11.77B | B+ | ||
| +4.66% | 10.13B | B+ | ||
| +27.92% | 8.59B | B | ||
| -6.04% | 7.42B | A- | ||
| +6.17% | 6.73B | B- | ||
| +4.29% | 6.48B | D | ||
| -3.73% | 4.35B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 000516 Stock
- Ratings Xi'an International Medical Investment Company Limited
